In this issue:
- RA disease activity and kidney function decline
- Leflunomide-associated peripheral neuropathy in NZ
- Pain catastrophising negatively impacts drug retention in PsA and axial SpA
- VTE risk with tofacitinib vs. anti-TNF in RA with increased CV risk
- Serious adverse events after TSR
- Gout flares after initiation of treat-to-target allopurinol and febuxostat
- Regional differences in clinical phenotypes of axial SpA
- Pain reduction with methotrexate in knee OA
- Predictive factors and treatment outcomes in difficult-to-treat RA
- Alcohol consumption and gout risk in men and women
Please login below to download this issue (PDF)